{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-088345","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.018620+00:00","generated_at":"2026-05-31T10:09:24.835367+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Journey Medical Q2 net product revenue $14.9M, net loss narrows to $3.4M; DFD-29 PDUFA Nov 4","bullets":["Total net product revenue $14.9M, down 12% YoY but up 14% sequentially from Q1 2024.","Net loss reduced to $3.4M ($0.17/sh) from $8.4M ($0.46/sh) in Q2 2023.","Adjusted EBITDA positive $0.3M vs negative $0.6M in prior-year quarter.","DFD-29 NDA for rosacea under FDA review with PDUFA goal date November 4, 2024.","Appointed Joseph M. Benesch as permanent CFO and Michael C. Pearce to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-088345","json":"https://secwatch.observer/filing/0001104659-24-088345.json","markdown":"https://secwatch.observer/filing/0001104659-24-088345.md","text":"https://secwatch.observer/filing/0001104659-24-088345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924088345/0001104659-24-088345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924088345/tm2421334d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:09:24.835367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}